Vyvanse Cost in Colorado 2026: Prices, Insurance, Savings, and Compounded Options

What Vyvanse Actually Costs at Colorado Pharmacies in 2026

The price you pay for Vyvanse in Colorado depends almost entirely on whether you use brand, generic, or compounded lisdexamfetamine, and whether you have insurance. Takeda's manufacturer list price remains $390 per month for brand-name Vyvanse [1]. That figure rarely reflects what patients hand over at the counter.

Generic lisdexamfetamine entered the U.S. market in August 2023 after the FDA approved abbreviated new drug applications from multiple manufacturers [2]. Since then, cash-pay prices have dropped considerably. Across Colorado retail pharmacies in 2026, the average cash-pay price with a discount card or coupon sits near $35 per month. That figure applies to the most commonly prescribed 30-capsule supply at standard doses (20 mg through 70 mg).

Prices vary by pharmacy. A King Soopers in Denver may quote differently than an independent pharmacy in Colorado Springs. Costco locations in the Front Range corridor tend to post some of the lowest per-unit generic prices in the state, though membership is not required for pharmacy purchases in Colorado under state law. Walmart and its associated Sam's Club pharmacies also price generics competitively. The spread between the cheapest and most expensive retail pharmacy for the same generic can be $15 to $40 for a 30-day supply, so calling ahead or checking a price comparison tool before filling is worth the two minutes it takes [3].

Colorado Medicaid and Vyvanse: What Is and Is Not Covered

Colorado Medicaid (Health First Colorado) does not cover Vyvanse or generic lisdexamfetamine for ADHD or binge eating disorder as of 2026. Coverage is limited to type 2 diabetes indications only. This is a significant gap for the roughly 1.5 million Coloradans enrolled in Medicaid or the Child Health Plan Plus (CHP+) program [4].

The Colorado Department of Health Care Policy and Financing maintains a preferred drug list (PDL) that determines which medications receive coverage without prior authorization. Stimulant medications for ADHD that do appear on the Colorado Medicaid PDL include certain formulations of mixed amphetamine salts and methylphenidate. Patients currently taking Vyvanse who transition to Medicaid coverage often need to work with their prescriber to switch to an alternative stimulant that is on the PDL.

Prior authorization requests for non-preferred stimulants can be submitted, but approval rates for lisdexamfetamine under Colorado Medicaid remain low when other preferred agents have not been tried first. The typical step-therapy requirement involves documented failure of or intolerance to at least two preferred stimulant options before Medicaid will consider an exception [4]. According to the American Academy of Family Physicians, "step-therapy protocols should balance cost containment with clinical judgment, particularly when a patient has a documented history of treatment response to a specific medication" [5].

How Insurance Plans in Colorado Handle Vyvanse

Commercial insurance plans in Colorado vary widely in how they tier lisdexamfetamine. Most large employer-sponsored plans and marketplace plans sold through Connect for Health Colorado place generic lisdexamfetamine on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), producing copays between $25 and $75 per fill.

Brand-name Vyvanse, when covered at all, typically falls on Tier 3 or the specialty tier, with copays or coinsurance running $75 to $150. Some plans have moved brand Vyvanse to "not covered" status now that generic equivalents exist, requiring the generic substitution at the pharmacy level.

Kaiser Permanente Colorado, one of the state's largest integrated plans, covers generic lisdexamfetamine with a standard specialty copay after the deductible is met. Anthem Blue Cross Blue Shield plans sold in Colorado generally require generic substitution and place lisdexamfetamine on Tier 2. Cigna and UnitedHealthcare plans, both prominent in the Colorado employer market, treat it similarly. Checking your specific plan's formulary before filling avoids surprises. The FDA notes that approved generic drugs must demonstrate bioequivalence to the reference listed drug, meeting the same standards for active ingredient, dosage form, strength, and route of administration [2].

The Takeda Savings Card: How It Works in Colorado

Takeda, the manufacturer of brand-name Vyvanse, offers a savings card program that can reduce out-of-pocket costs for commercially insured patients. The card provides up to $60 off per prescription fill, with a maximum annual benefit that resets each calendar year [1].

Eligibility rules matter. The card is available to patients with commercial insurance only. It cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program. Colorado patients on Health First Colorado are excluded. The card also cannot be combined with certain copay accumulator or copay maximizer programs that some Colorado insurers have adopted. Under these programs, manufacturer copay assistance does not count toward your deductible or out-of-pocket maximum.

For commercially insured patients whose plan covers brand Vyvanse with a copay of $60 or less, the savings card can reduce the out-of-pocket cost to $0. For those with higher copays, the card reduces the total by $60. Given that generic lisdexamfetamine is now available at roughly $35 with a discount tool, the savings card's primary value is for patients whose insurance specifically requires the brand product or whose prescriber has written "dispense as written" on the prescription.

Compounded Lisdexamfetamine in Colorado: Legality and Access

Compounded lisdexamfetamine is legal in Colorado through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act [6].

Several points distinguish compounded from manufactured generic. Compounded formulations are not FDA-approved products. They do not undergo the same bioequivalence testing that manufactured generics require. The FDA has stated that "compounded drugs are not FDA-approved, which means they have not been verified for safety, effectiveness, or quality" [6]. This does not make them illegal. It means the prescriber and patient accept a different regulatory framework.

In Colorado, compounding pharmacies must hold a valid Colorado State Board of Pharmacy license and comply with USP 795 standards for non-sterile compounding. Patients seeking compounded lisdexamfetamine need a valid prescription from a licensed prescriber who has established a patient-provider relationship. Compounded versions may be offered at lower cost points than manufactured generics, particularly for patients without insurance or those whose insurance does not cover any form of lisdexamfetamine.

Colorado does not impose additional state-level restrictions on the compounding of Schedule II controlled substances beyond federal DEA requirements. The prescribing provider must hold a valid DEA registration, and the compounding pharmacy must maintain its own DEA registration for Schedule II handling [7].

Telehealth Prescribing of Vyvanse in Colorado

Colorado permits the prescribing of Vyvanse and generic lisdexamfetamine via telehealth. This has been the case since the state adopted expanded telehealth provisions, and Colorado law does not require an in-person visit before a controlled substance can be prescribed when a legitimate medical evaluation has been conducted via audio-visual telehealth [8].

Federal rules matter here too. The DEA's telemedicine prescribing framework for Schedule II controlled substances has undergone multiple extensions and revisions since 2020. As of 2026, the DEA permits telehealth prescribing of Schedule II stimulants when specific conditions are met, including a real-time audio-visual evaluation and appropriate documentation of the medical decision-making process [7].

Colorado-based telehealth platforms and out-of-state providers licensed in Colorado can both prescribe lisdexamfetamine to Colorado residents. The Ryan Haight Online Pharmacy Consumer Protection Act still applies: the prescription must result from a qualifying telemedicine encounter as defined under the Act [7]. Wigal et al. demonstrated in a 2017 study (N=314) that lisdexamfetamine produced statistically significant improvements in ADHD symptom scores compared to placebo across multiple dose levels, with an effect size (Cohen's d) of 0.80 to 1.20, supporting its first-line use when prescribed through any legitimate clinical pathway including telehealth [9].

Colorado Discount Programs Beyond the Savings Card

Multiple discount pathways exist for Colorado residents who need lisdexamfetamine and lack adequate insurance coverage. These programs operate independently of insurance.

Prescription discount cards from GoodRx, RxSaver, and similar aggregators pull negotiated rates from pharmacy benefit managers and pass those prices to uninsured or underinsured patients. The $35 average cash-pay price cited earlier reflects the use of these tools. Prices update frequently, sometimes weekly, and differ by pharmacy location. A 80-character text to a price-checking service can save $20 on a single fill.

Takeda's patient assistance program, Takeda HELP at Hand, provides brand-name Vyvanse at no cost to qualifying patients who meet income requirements (generally household income at or below 300% of the federal poverty level). The application requires documentation of income and a signed prescription from the prescriber [1].

Colorado's own 340B Drug Pricing Program participants, including federally qualified health centers (FQHCs) such as Salud Family Health Centers, Denver Health, and Clinica Family Health, can dispense medications at 340B-discounted prices to eligible patients. The 340B discount on brand-name Vyvanse can be substantial, often reducing the cost by 25% to 50% below the wholesale acquisition cost [10]. Colorado has over 200 340B-covered entities across the state.

The Needymeds database lists additional manufacturer and charitable assistance programs available to Colorado residents. Checking multiple pathways before each fill is practical, not obsessive. Prices shift quarter to quarter.

Lisdexamfetamine Dosing, Formulation, and Clinical Context

Lisdexamfetamine dimesylate is a prodrug of dextroamphetamine. The body converts it to active dextroamphetamine after oral ingestion, primarily through enzymatic hydrolysis in red blood cells [9]. This prodrug mechanism produces a smoother pharmacokinetic profile compared to immediate-release amphetamine formulations, with a duration of action typically lasting 10 to 14 hours.

The FDA approved lisdexamfetamine for ADHD in patients aged 6 years and older and for moderate-to-severe binge eating disorder (BED) in adults [2]. Available capsule strengths include 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. Most adults with ADHD are titrated to an effective dose between 30 mg and 70 mg daily, taken once in the morning.

A 2017 study by Wigal et al. published in the Journal of Attention Disorders evaluated lisdexamfetamine in a randomized, double-blind, placebo-controlled trial of 314 adults with ADHD. The primary endpoint, change from baseline on the ADHD Rating Scale IV, showed statistically significant improvement across all active dose groups (30 mg, 50 mg, and 70 mg) compared to placebo (P<0.001 for each comparison) [9]. The most common adverse effects were decreased appetite (27%), dry mouth (26%), and insomnia (19%).

For binge eating disorder, the FDA approval was based on two Phase III trials totaling 724 adults, in which lisdexamfetamine 50 mg and 70 mg produced a significant reduction in binge eating days per week compared to placebo. The 70 mg dose reduced binge days from a baseline mean of 4.5 to 0.9 per week at 12 weeks [2]. The Endocrine Society's clinical practice guidelines note that pharmacotherapy for BED should be considered alongside structured behavioral interventions, and that "lisdexamfetamine is the only FDA-approved medication for the treatment of moderate-to-severe binge eating disorder in adults" [11].

Comparing Your Options: Brand vs. Generic vs. Compounded in Colorado

The practical decision for most Colorado patients comes down to three columns: brand Vyvanse, generic lisdexamfetamine, and compounded lisdexamfetamine. Each carries different cost, regulatory, and clinical trade-offs.

Brand Vyvanse at $390 list price makes sense only when a patient's insurance covers brand with a low copay and the Takeda savings card brings the out-of-pocket cost below the generic alternative. This scenario is becoming rare as insurers mandate generic substitution.

Generic lisdexamfetamine at approximately $35 per month (cash-pay with discount) or $25 to $75 (insurance copay) is the default for most patients in 2026. Multiple manufacturers produce it. FDA bioequivalence standards ensure that pharmacokinetic parameters (AUC and Cmax) fall within 80% to 125% of the reference product [2].

Compounded lisdexamfetamine through a 503A pharmacy may cost less, but patients should discuss with their prescriber whether a non-FDA-approved formulation is appropriate for their clinical situation. The lower price point appeals to uninsured patients, though manufactured generics have narrowed the cost gap significantly since 2023.

Patients filling at a Colorado pharmacy should confirm whether their insurance applies a copay accumulator program, which can affect total annual out-of-pocket costs by preventing manufacturer copay assistance from counting toward the deductible. Colorado has considered but not yet enacted copay accumulator reform legislation as of May 2026 [4].